ADNI Sponsors and Partners

(Click the links to download these presentations)

ADNI Symposium Presentation

Presentation to ICAD
July 27, 2008 
Dr. Michael W. Weiner

ADNI Preliminary Results, July 2008: Comparative and Longitudinal Results

Presentation to ISAB at ICAD, Chicago

ADNI Biostatistics Core, UC Davis
Laurel Beckett, PhD
Danielle Harvey, PhD
Hao Zhang, MS

ICAD Chicago 2008 ADNI Abstracts

Oral Presentations

i.    Weiner MW. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Progress Report. S1-01-01, Page T99. (PL-05-02) The evolution of Alzheimer's disease clinical trial design

ii.    Paul S. Aisen, University of California, San Diego, San Diego, CA, USA. Plenary PL-05. Plenary 5

iii.    Apostolova LG, Morra JH, Green AH, Hwang K, Avedissian C, Parikshak N, Cummings JL, Toga AW, Jack CR, Weiner MW, Thompson PM. Automated Longitudinal 3-D Mapping of Hippocampal ADAS-cog Delayed Recall Effects in 293 Normal Elderly, Mild Cognitive Impairment and Alzheimer’s Disease Subjects. O1-02-05, Page T110.

iv.    Reiman EM, Chen K, Ayutyanont N, Lee W, Bandy D, Reschke C, Alexander GE, Weiner MW, Koeppe RA, Foster NL, Jagust WJ. Twelve-Month Cerebral Metabolic Declines in Probable Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings From the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

v.    Schuff N, Woerner N, Boreta L, Kornfield T, Jack Jr. CR, Weiner MW. Rate of Hippocampal Atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Effects of ApoE4 and Value of Additional MRI Scans. O3-03-06, Page T164.

vi.    Donohue M, Aisen P, Gamst A, Weiner M. Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Data to Improve Power For Clinical Trials

Posters

i.    Alexander GE, Hanson KD, Chen K, Reiman EM, Bernstein MA, Kornak J, Schuff NW, Fox NC, Thompson PM, Weiner MW, Jack CR. Six-Month MRI Gray Matter Declines in Alzheimer Dementia Evaluated by Voxel-Based Morphometry with Multivariate Network Analysis: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-03-06, Page T8, & P1-216, Page T273.

ii.    Foster NL, Wang AY, Levy JA, Koeppe RA, Jagust WJ, Chen K, Reiman EM, Weiner MW. Frequency of Hemispheric Metabolic Asymmetry in Probable Alzheimer’s Disease. IC-P2-098, Page T47 & PI-244, Page T286.

iii.    Landau SM, Madison C, Wu D, Cheung C, Foster N, Reiman E, Koeppe R, Weiner M, Jagust WJ. Pinpointing Change in Alzheimer’s Disease: Longitudinal FDG-PET Analysis From the Alzheimer’s Disease Neuroimaging Initiative (ADNI). PI-258, Page T291.

iv.    Chen K, Lee W, Liu X, Alexander G, Bandy D, Reschke C, Foster N, Weiner M, Koeppe R, Jagust W, Reiman E. The Consistency of Hypometabolic Brain Voxels in Probable Alzheimer’s Disease and Amnestic Mild Cognitive Impairment Patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). PI-338, Page T318.

v.    Gunter JL, Borowski B, Bernstein M, Ward C, Britson P, Felmlee J, Schuff N, Weiner M, Jack C. Systematics of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Phantom. P2-011, Page T369.

vi.    Gunter JL, Borowski B, Britson P, Bernstein M, Ward C, Felmlee J, Schuff N, Weiner M, Jack C. Alzheimer’s Disease Neuroimaging Initiative (ADNI) Phantom and Scanner Longitudinal Performance. P2-012, Page T370.

vii.    Lee W, Langbaum JBS, Chen K, Recshke C, Bandy D, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM. Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-P1-036, Page T23 & P2-037, Page T379.

viii.    Petersen RC, Aisen P, Beckett L, Donohue M, Weng Q, Salmon D, Weiner M. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Baseline Characteristics. P3-040, Page T528.

ix.    Yang DW, Rosen HJ, Gorno-Tempini M-L, Miller BL, Kramer JH, Weiner M, Sollberger M. Structural Anatomy of Environmental Dependency Syndrome in Neurodegenerative Disease. IC-P1-068, Page T35.

x.    Chen K, Reschke C, Lee W, Bandy D, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM. The Pattern of Cerebral Hypometablism in Amnestic Mild Cognitive Impairment and Its Relationship to Subsequent Conversion to Probable Alzheimer’s Disease: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative. IC-P2-086, Page T42.

xi.    Madison C, Landau S, Cheung C, Lal R, Foster N, Reiman E, Koeppe R, Weiner M, Jagust W. Meta-Analysis ROIs and Minimal Deformation Templates Improve PET-FDG as a Candidate Biomarker in Alzheimer’s Disease. IC-P2-114, Page T53.

xii.    Reiman EM, Chen K, Ayutyanont N, Lee W, Bandy D, Reschke C, Alexander GE, Weiner MW, Koeppe RA, Foster NL, Jagust WJ. Twelve-Month Cerebral Metabolic Declines in Probable Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative. IC-P2-128, Page T58.

xiii.    Gunter JL, Borowski B, Britson P, Bernstein M, Ward C, Felmlee J, Schuff N, Weiner M, Jack CR, the Alzheimer’s Disease Neuroimaging Initiative. ADNI Phantom & Scanner Longitudinal Performance. IC-P3-181, Page T80.

xiv.    Mueller S, Schuff N, Raptentsetsang S, Yaffe K, Madison C, Miller B, Weiner M.  Patterns of Hippocampal Atrophy in Alzheimer’s Disease, Mild Cognitive Impairment and APOE4. IC-P3-200, Page T86.

xv.    Schuff N, Woerner N, Boreta L, Kornfield T, Jack Jr. CR, Weiner MW.  Rate of Hippocampal Atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Effects of APOE4 and Value of Additional MRI Scans. IC-P3-213, Page T91.

xvi.    Thompson P, Apostolova LG, Morra JH, Green AE, Hwang K, Avedissian C, Parikshak N, Cummings JL, Toga AW, Jack CR, Weiner MW. Automated Longitudinal 3D Mapping of Hippocampal ADASCPG Delayed Recall Effects in 293 Normal Elderly, MCI and AD Subjects. IC-P3-223, Page T95.

ADNI/Initiative: Other Related

Oral Presentations

i.    Frisoni GB. The Pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI) of the European Alzheimer’s Disease Consortium. S1-01-02, Page T99.

ii.    Saykin AJ. Integrating Neuroimaging, Genomics and Cognition in Alzheimer’s Disease Research. IC-PL1, Page T1.

Posters

i.    Carmichael OT, Drucker D, Schwarz C, Fletcher E, Martinez O, Yoshita M, He J, DeCarli C. Longitudinal Changes in Cognition and Cerebrovascular Disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-03-05, Page T7 & P1-227, Page T277.

ii.    Davatzikos C, Fan Y, Clark CM. MRI-Based High-Dimensional Pattern Classification of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimer’s Disease, Mild Cognitive Impairment and Healthy Controls Reveals Patterns of Atrophy Used for Individual Classification and Predicts Subsequent Cognitive Decline. IC-P2-088, Page T43 & P1-233, Page T280.

iii.    Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells J, Bartha R. Longitudinal Association Between the Apolipoprotien -e4 Gene Polymorphism and Cerebral Ventricular Dilatation Measured from Serial Magnetic Resonance Imaging in Subjects Participating in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-P3-202, Page T87 & P1-271, Page T296.

iv.    Zhang H, Wu T, Bae M-H, Reiman EM, Alexander GE, Thompson PM, Jack Jr. CR, Chen K. Use of the Support Vector Machine and Sensitivity of an Alzheimer’s Disease-Related Region-Of-Interest Gray Matter Classifier in Identifying Amnestic Mild Cognitive Impairment Subjects Who Convert to Alzheimer’s Disease: Preliminary Findings from the Alzheimer’ Disease Neuroimaging Initiative (ADNI). P1-311, Page T312.

v.    Carmichael OT, Drucker D, Fletcher E, Ortega M, He J, Yoshita M, DeCarli C. Baseline MRI Measures of Cerebrovascular Disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-P2-085, Page T42 & P1-333, Page T316.

vi.    Huang J, Auchus AP. Lobar Gray and White Matter Atrophy in Alzheimer’s Disease: Preliminary Results from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Public Database. IC-P3-184, Page T81 & P2-017, Page T371.

vii.    McEvoy LK, Karow DS, Fennema-Notestine C, Hagler DJ, Roddey JC, Holland D, Jennings RG, Brewer JB, Dale AM. Regional Metabolism in Mild Cognitive Impairment Predicts Clinical Decline and Structural Volume Loss: Initial Results from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). IC-P2-115, Page T53 & P2-051, Page T381.

viii.    Davatzikos C, Fan Y, Clark CM. Hippocampal and Distributed Gray Matter Abnormalities in Mild Cognitive Impairment and Early Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Baseline 1.5T MRI Scans: Cross-Sectional Analysis And Relation to Verbal Learning

ix.    Shaw LM, Vanderstichele H, Knapik-Czajka M, Blennow K, Soares H, Simon A, Lewczuk P, Siemers E, Dean R, Potter WZ, Lee VM-Y, Trojanowski JQ. Characterization of CSF A Beta 1-42, Tau and P-Tau181P Concentrations at Baseline in Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study Patients. P3-093, Page T545.

x.    Evans MC, Nielsen C, Douiri A, Barnes J, Clegg SL, Lehmann M, Mellow T, McNaught E, Ahsan L, Boyes R, Pepple T, Foster J, Rossor MN, Fox NC. Automating the BSI Brain Atrophy Rate Calculation: Comparison of Using Automated and Semi-Automated Brain Regions. IC-P2-094, Page T45 & P2-007, Page T367.

xi.    Saykin AJ, West JD, Shen L, Firpi HA, Wessels A, Cannon A, Risacher S, McDonald BC, and the Alzheimer’s Disease Neuroimaging Initiative. Hippocampal and Distributed Gray Matter Abnormalities in Mild Cognitive Impairment and Early Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative Baseline 1.5T MRI Scans: Cross-Sectional Analysis and Relation to Verbal Learning. IC-P2-132, Page T59 & P2-072, Page T388.

xii.    Smith ME, Chen GN, Magda S, Airriess C, Marinkovic K. Validation of a Fully-Automated Medical Device for Quantifying Regional Brain Atrophy from MRIs of Patients with Alzheimer’s Disease and Related Disorders. IC-P3-219, Page T93 & P2-082, Page T393.

xiii.    Ayutyanont N, Chen K, Liu X, Reschke C, Lee W, Bandy D, Alexander GE, Jagust WJ, Koeppe RA, Foster NL, Reiman EM. Differentiating Amnestic MCI Converting to Probable AD from Stable Amnestic MCI Using FDG-PET and an AD-Related Hypometabolism Overlap Index. IC-P2-074, Page T38 & P1-312, page T312.

xiv.    Brewer JB, Holland DJ, Fennema-Notestine C, Dale AM. Brain Structure Change is Associated With Clincial Decline of Elderly Controls: A Longitudinal Study Using the ADNI Dataset. IC-P2-080, Page T40.

xv.    Davatzikos C, Xu F, Resnick SM. Longitudinal Progression of AD-Like Patterns of Brain Atrophy in a Normal Elderly Cohort and in MCI: A High-Dimensional Pattern Classification Study. IC-P2-090, Page T43 & P1-232, Page T280.

xvi.    Edland SD, Holland D, Fennema-Notestine C, Hagler DJ, McEvoy LK, Brewer JB, Dale AM, the Alzheimer’s Disease Neuroimaging Initiative. The Relative Performance of Different Structural MRI Measures as Outcomes in Secondary Prevention Trials: Statistical Considerations of Power and Sample Size. IC-P2-092, Page T44.

xvii.    Querbes O, Lotterie JA, Pariente J, Berry I, Fort JC, Aubry F, Celsis P. MRI-Based Cortical Thickness Measurement Improves the Prediction of MCI to AD Conversion. IC-P2-126, Page T57.

xviii.    Xu G, Fitzgerald ME, Sager MA, Asthana S, Johnson SC. Detecting Early Onset of Alzheimer’s Disease with MR ASL, FDG PET, PIB PET and O15 PET: A Multi-Modal Neuroimage Approach. IC-P2-156, Page T69.

xix.    Fletcher PT, Wang AY, Foster NL, Joshi SC. Quantifying Metabolic Asymmetry in Alzheimer’s Disease Using Both MR and PET Imaging. IC-P3-179, Page T79 & P1-243, Page T286.

 xx.    Cronk BB, Johnson DK, Harsha A, Burns JM. Body Composition is Associated with Cognitive Decline in Mild Cognitive Impairment. P1-183, Page T262.

xxi.    Edland SD, McEvoy LK, Holland D, Roddey JC, Fennema-Notestine C, Brewer JB, Dale AM, The Alzheimers’ Disease Neurimaging Initiative. Enrichment Strategies for Secondary Prevention Trials: The Effect of Restrictive Inclusion Criteria on Statistical Power and Sample Size. P1-188, Page T263.

xxii.    Jacobson MW, McEvoy L, Fennema-Notestine C. Frequency of Cognitive Discrepancies in Mild Cognitive Impairment Subtypes. P1-192, Page T265.

xxiii.    Holland D, Hagler DJ, Fennema-Notestine C, Dale AM. Longitudinal Nonlinear Registration and Quantitative Analysis of Change in Whole Brain and Regions of Interest. P1-249, Page T288.

xxiv.    Grundman M, Black R, Liu E, Motalli R, Zawadzki R, McLaughlin T. The Neuropsychological Test Battery Discriminates Patients with Mild Cognitive Impairment from Normal Controls and Alzheimer’s Disease. P3-137, Page T560.

xxv.    Tractenberg RE. Latent Variable Modeling of ‘Hard’ Endpoints and Multiple Outcomes in Neuroimaging Data. P2-090, Page T396.

xxvi.    Duchesne S, Frisoni G. High Specificity in Automated Computer Classification of Probable AD Using Multi-Site ADNI MRI. IC-P1-022, Page T17.

xxvii.    Evans MC, Barnes J, Clegg SL, Lehmann M, Mellow T, McNaught E, Ahsan L, Boyes R, Pepple T, Foster J, Nielsen C, Rossor MN, Fox NC. Rates of Whole Brain Atrophy and Ventricular Enlargement: Correlations with Cognitive Performance. IC-P2-095, Page T45 & P1-240, Page T283.

xxviii.    Spenger C, Westman E, Segerdahl T, Bengtsson J, Wahlund L-O, Soininen H, Kononen M, Tsolaki M, Mauredaki P, Mecocci P, Tarducci R, Kloszewska I, Sobow T, Vellas B, Payoux P, Evans A, Muehlboeck S, Julin P, Simmons A, Lovestone S, on behalf of the AddNeuroMed Consortium. The INNOMED/ADDNEUROMED Framework for Multicenter MRI Assessment of Longitudinal Changes in Alzheimer’s Disease. O1-02-08, Page T111.

xxix.    Simmons A, Westman E, Segerdahl T, Bengtsson JO, Wahlund L-O, Zhang Y, Soininen H, Vellas B, Mecocci P, Kloszewska I, Evans A, Muehlboeck S, Julin P, Lovestone S, Spenger C, on behalf of the AddNeuroMed Consortium. Early Magnetic Resonance Imaging Results from the ADDNEUROMED Alzheimer’s Disease Study.